Mounjaro

Lilly's Mounjaro and Zepbound sales hit $16.1 billion as it raises its 2026 forecast

Eli Lilly's revenue rose 39% to $24.4 billion in July through September as Mounjaro and Zepbound sales climbed, even as the prices Lilly collected fell. It now expects 2026 revenue of $91 billion to $92 billion.